Compare GoPro Inc (GPRO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Recursion Pharmaceuticals Inc — how do they compare? GoPro Inc trades at $1.18 (market cap $253.82M), while Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.31B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 9.1× GoPro Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (40,478,768 versus 9,909,466). Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| GPRO | RXRX | |
|---|---|---|
Market Cap | $253.82M | $2.31B |
Volume | 9,909,466 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $2.35 | $6.79 |
52-Week Low | $0.58 | $2.84 |
Typical Hold Time | 45 Days | 22 Days |
Enterprise Value | $312.60M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.18, down 10.61% today amid volatile trading following recent merger announcements. The stock shows bullish technical signals with oversold RSI conditions, while fundamentally the company faces significant challenges with negative profit margins and declining revenue. Recent developments include a proposed $285 million merger with Starman Optical and influencer Markiplier taking an 8.5% stake, driving substantial price volatility.
Investment outlook remains highly speculative with the merger offering potential upside from the $1.14 buyout price, but fundamental weakness and negative cash flow pose substantial risks. Analyst sentiment is mixed with only 21% recommending buy, while ongoing investigations into the merger's fairness add uncertainty to the transaction's completion.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
